OXFORD, England, July 12, 2011 /PRNewswire/ -- PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by Avexa Limited to seek an out-licensing partner for apricitabine (ATC), a late-stage, novel treatment for HIV infection.

-- Progen board; - finally accepts legitimate call by shareholders to general Meeting; - will not allow shareholder vote on full share buyback; and - persists with high risk, high funding, Avexa merger proposal.

MELBOURNE, Australia, Feb.

Australian biotechnology company Avexa (ASX:AVX) today announced the presentation of 48 week data from its apricitabine program at the Ninth International Congress on Drug Therapy in HIV Infection held in Glasgow, UK, 9-13 November 2008.

Melbourne-based biotechnology company Avexa Limited (ASX:AVX) announced excellent 48 week data from apricitabine's (ATC) phase 2b clinical trial. At week 48 the proportion of patients with HIV levels below detectable was over 90%.